Listen to the article
PureHealth Holding has announced strong financial results for the fiscal year ending December 31, 2025, with net profits growing 17.7% year-on-year to reach 2 billion dirhams. The Abu Dhabi-based healthcare group also proposed a dividend distribution of 600 million dirhams for 2025, subject to regulatory and shareholder approval, reflecting its robust financial position and commitment to shareholder returns.
According to the company’s statement, PureHealth’s revenues reached 27.3 billion dirhams during 2025, marking a 5.7% increase compared to the previous year. The growth was driven by strong performance in both the healthcare and insurance sectors, while pre-tax profits rose 26.1% annually to 2.2 billion dirhams.
Strong Operational Efficiency Drives PureHealth Financial Performance
The healthcare group reported that earnings before interest, taxes, depreciation, and amortization climbed 16.1% compared to the prior year, reaching 4.8 billion dirhams. This improvement resulted from continuous enhancements in operational efficiency and integration between operations, according to the company. Additionally, the contribution from Hellenic Healthcare Group during the fourth quarter of 2025, following the recent acquisition in Greece and Cyprus, bolstered overall performance.
The proposed dividend distribution of 600 million dirhams represents approximately 30% of net profits and will be distributed in two equal semi-annual installments. However, the distribution remains contingent upon receiving necessary approvals from regulatory authorities and shareholders. This dividend policy underscores the strength of PureHealth’s balance sheet and its recurring earnings base.
International Expansion Strengthens Revenue Diversification
PureHealth currently operates across the United Arab Emirates, the United States, the United Kingdom, Greece, and Cyprus. The company’s geographic diversification strategy has proven successful, with approximately 50% of assets now located outside the UAE. This international footprint provides the healthcare group with diversified revenues across multiple markets and currencies, reducing concentration risk.
Kamal Al Mazmi, Chairman of PureHealth’s Board of Directors, stated that 2025 represented a pivotal milestone in the company’s journey toward building an integrated global healthcare group supported by technology and innovation. Meanwhile, the expansion into strategic international markets and enhancement of specialized care capabilities domestically have established foundations for a more interconnected and resilient healthcare system.
Technology and AI Investment Central to Growth Strategy
The healthcare provider continues to invest heavily in artificial intelligence-powered healthcare solutions and digital technologies. According to Shaista Asif, Chief Executive Officer of PureHealth Group, the scope of digital solutions and AI applications being implemented creates an exceptional platform that distinguishes the company from major global healthcare entities. In contrast to traditional healthcare models, this technology-driven approach positions PureHealth to lead the AI-supported healthcare era.
Farhan Malik, Founder and Managing Director of PureHealth Group, emphasized that resilient financial performance and balance sheet strength form the foundation for the group’s disciplined capital deployment approach. The company continues pursuing value-enhancing acquisitions alongside investments in technology, AI, and capacity expansion. These strategic investments aim to deliver stronger returns for shareholders while bringing best-in-class healthcare standards to the UAE and other served markets.
Market Demand and Capacity Expansion Support Revenue Growth
Several factors contributed to PureHealth’s revenue growth throughout 2025. Growing demand for healthcare services, expansion of clinical capacity, and delivery of specialized medical services all played significant roles. Furthermore, the integration of Circle Health Group in the United Kingdom generated strong momentum, while the successful incorporation of the Hellenic Healthcare Group acquisition in Greece and Cyprus added to fourth-quarter performance.
The healthcare group’s care and insurance model has demonstrated its ability to convert operational scale into strong profits and cash flows. This integrated approach enables meaningful synergies across different markets, according to company executives. Additionally, the recurring nature of the earnings base provides sustainable cash generation capacity across various sector conditions.
The proposed dividend distribution and financial results require final approval from regulatory bodies and shareholders before implementation. The company has not announced specific dates for shareholder meetings or regulatory review timelines, though approvals are expected to follow standard procedural requirements in the coming months.
